SRPT · Sarepta Therapeutics
AI read · Good for SRPT
The AI's read
PMO sales are the clearest support for Sarepta's stronger sales outlook. The company also reported continued profit and cash generation, which can fund research. Elevidys demand has only steadied. Enrollment forms matched the prior quarter, so the improvement does not show a clear recovery in that part of the business. The stronger PMO business and higher sales forecast outweigh the limited Elevidys improvement, making the report positive for Sarepta.